17 July 2020 Malaysia Minister Claims Imported Sofosbuvir Supply Enough For Malaysian Hepatitis C Patients MOH said last November that 4,500 Malaysians were treated with generics of sofosbuvir.
26 May 2020 Opinion What Is A Covid-19 Cure Worth? Compulsory licencing may not necessarily guarantee widespread access of remdesivir to Covid-19 patients in Malaysia.
22 May 2020 Letter There Is No Reason To Accept High Prices For Covid-19 Treatments — Mark Cheong Wall Street analysts suggest remdesivir could be priced between US5,000-US10,000 for a 10-day course of treatment.
21 May 2020 Malaysia Malaysia To Use ‘Other Means’ Of Getting Remdesivir If Effective For Covid-19 Gilead Sciences has excluded Malaysia from receiving generic versions of remdesivir.
21 May 2020 Malaysia Malaysia Not Rich, Affordable Remdesivir Needed, MPs Tell Gilead Three Opposition MPs say Malaysia can’t afford to spend as much on health care as Singapore or other Asian countries like South Korea.
20 May 2020 Malaysia Why Malaysia May Lose Generic Access To Potential Covid-19 Drug The only three Asean countries excluded by Gilead Sciences for generic versions of remdesivir in its new licencing agreements are Malaysia, Singapore, and Brunei.
19 May 2020 Letter Include Malaysia And Other Middle-Income Countries in All Licensing Agreements For Covid-19 Diagnostics, Treatments, And Vaccines — MHC & DNDi Gilead excluded Malaysia, among other middle-income countries, from distribution of Remdesivir to 127 nations under voluntary licensing.
12 May 2020 World Expensive Future Covid-19 Medicine Will Worsen Inequality: Study Unwarranted high prices for medications could lead to preventable deaths, said a study.
20 April 2020 World US Hospital Sees Early Success In Gilead Drug Treating Covid-19 The trial saw most patients with severe Covid-19 discharged within six days.